Scholars Academic Journal of Biosciences
Abbreviated Key Title: Sch Acad J Biosci
ISSN 2347-9515 (Print) | ISSN 2321-6883 (Online)
Journal homepage: https://saspublishers.com
National Library of Medicine
NLM ID:101629416

OPEN ACCESS

Biochemistry

Gene Editing at the Crossroads of Biochemistry and Biotechnology Exploring the Molecular Precision and Therapeutic Potential of CRISPR and Beyond

Mariam[1*], Safa Maryam[1], Md Mehedi Hasan[2], Masooma Haider[3], Gulshan Asghar[4], Muhammad Adnan Qadar[5], Romesa Zafar[6]

[1]Department of Biochemistry, University of Agriculture Faisalabad, Punjab, Pakistan
[2]Senior Executive, SQUARE Pharmaceuticals PLC, MS in Microbiology, University of Dhaka, Bangladesh
[3]Graduate Institute of Biological Science and Technology China Medical University, Taiwan
[4]Institute of Horticultural Sciences, University of Agriculture Faisalabad, Punjab Pakistan
[5]Division of Science and Technology, University of Education Township, Lahore
[6]Department of Molecular Genetics, Department of Biosciences, COMSATS University Islamabad

DOI: https://doi.org/10.36347/sajb.2025.v13i08.003 | **Received:** 11.06.2025 | **Accepted:** 04.08.2025 | **Published:** 05.08.2025

***Corresponding author:** Mariam
Department of Biochemistry, University of Agriculture Faisalabad, Punjab, Pakistan

Abstract | **Review Article**



Graphical Abstract

At the front edge of contemporary research, gene editing connects the complex fields of biochemistry and biotechnology. This review paper explores the molecular mechanics, biochemical precision, and ground-breaking therapeutic development applications of CRISPR and other new gene-editing tools, highlighting their transformational influence. Starting with the fundamental understanding of CRISPR-Cas systems, the review focuses on how developments in enzymology and structural biology have shed light on the exact interactions that control target identification and cleavage. We look at how these instruments have quickly progressed from simple bacterial defense mechanisms to programmable genome-editing tools with unmatched diversity and specificity. The study also examines next-generation methods, including as base editing, prime editing, and epigenome editing, highlighting their improved safety profiles and biochemical enhancements. Additionally examined is the intersection of gene editing, omics, and AI, which opens

up new avenues for precision medicine, diagnostics, and disease modeling. The therapeutic promise of gene editing in treating infectious illnesses, cancer, and genetic abnormalities is emphasized, along with important issues including delivery methods, off-target consequences, and ethical issues. Furthermore, it is explored how biochemical breakthroughs are enhancing editing fidelity, transport vectors, and enzyme engineering, demonstrating how these developments are influencing the direction of clinical applications in the future. The study also examines next-generation methods, including as base editing, prime editing, and epigenome editing, highlighting their improved safety profiles and biochemical enhancements. Additionally examined is the intersection of gene editing, omics, and AI, which opens up new avenues for precision medicine, diagnostics, and disease modeling. The therapeutic promise of gene editing in treating infectious illnesses, cancer, and genetic abnormalities is emphasized, along with important issues including delivery methods, off-target consequences, and ethical issues. Furthermore, it is explored how biochemical breakthroughs are enhancing editing fidelity, transport vectors, and enzyme engineering, demonstrating how these developments are influencing the direction of clinical applications in the future.

Keywords: CRISPR-Cas Systems, Molecular Gene Editing, Biochemical Mechanisms, Programmable Nucleases, Gene Therapy Applications, DNA Repair Pathways, Cas Protein Engineering, Precision Genome Engineering, RNA-Guided DNA Cleavage.

INTRODUCTION

Over the past 20 years, gene editing technologies have advanced remarkably, radically altering the field of molecular biology and therapeutic research (Li *et al.,* 2020). Zinc Finger Nucleases (ZFNs), one of the first programmable nucleases created to precisely modify the genome by causing specific double-strand breaks in DNA, marked the beginning of the trip (Burgess *et al.,* 2020). To identify certain DNA sequences, ZFNs use modified zinc finger proteins coupled to a nuclease domain; yet, their intricate structure and narrow targeting range presented difficulties. Using adaptable DNA-binding domains from plant diseases, Transcription Activator-Like Effector Nucleases (TALENs) subsequently surfaced, providing better specificity and simpler design than ZFNs (Ochiai *et al.,* 2014). TALENs made genome editing more effective and adaptable, increasing its uses in a variety of species. CRISPR-Cas9, in contrast to ZFNs and TALENs, uses a guide RNA molecule to lead the Cas9 nuclease to complementary DNA regions (Gupta *et al.,* 2014). This enables simple retargeting by only changing the RNA sequence. Because of its extraordinary accuracy, multiplexing capabilities, and ease of design, CRISPR is now the most widely used genome editing tool. Furthermore, by permitting precise nucleotide modifications without double-strand breaks, minimizing off-target consequences, and increasing therapeutic potential, recent advancements in CRISPR variants, such as base editors and prime editors, are pushing the envelope even farther (Saber Sichani *et al.,* 2023). All things considered, the development of ZFNs, TALENs, and ultimately CRISPR-Cas systems shows a trend toward greater accuracy, effectiveness, and usability, signaling a paradigm change in genetic engineering with significant ramifications for biotechnology, medicine, and agriculture (Sampath *et al.,* 2023).

A single-guide RNA (sgRNA) uses complementary base pairing to guide the Cas9 nuclease to a particular genomic sequence (Butt *et al.,* 2017). Specificity is further guaranteed by identifying a protospacer adjacent motif (PAM) close to the target site. This RNA-guided DNA targeting mechanism is the basis for the accuracy and adaptability of CRISPR systems, particularly CRISPR-Cas9 (Hu *et al.,* 2023). A precise double-stranded DNA break is produced when Cas9's two nuclease domains (HNH and RuvC) are activated by conformational changes brought on by binding to the PAM. To minimize off-target effects, this procedure depends on the creation of an RNA-DNA hybrid (R-loop) that displaces the non-target strand and permits cleavage only when precise base pairing and PAM presence are verified (Allen *et al.,* 2025). CRISPR is a very accurate and flexible tool for genome engineering because, after cleavage, cellular DNA repair pathways like non-homologous end joining or homology-directed repair allow for a variety of editing outcomes. Additionally, engineered Cas variants and fusion proteins further improve specificity and expand functional applications (Cebrian-Serrano *et al.,* 2017).

With revolutionary technologies like CRISPR-Cas systems, TALENs, and base editors permitting previously unheard-of accuracy in altering genomic sequences, the field of gene editing has swiftly changed, transforming molecular biology and the creation of new treatments (Chanchal *et al.,* 2024). Notwithstanding these developments, there are still some important drawbacks, such as immunological reactions, off-target effects, delivery difficulties, and a lack of knowledge about the underlying molecular processes controlling enzyme specificity and DNA repair pathways. To improve editing efficiency and safety, these limitations underscore the pressing need for more profound biochemical understanding of enzyme-substrate interactions, DNA recognition patterns, chromatin accessibility, and cellular context-dependent dynamics (Rallapalli *et al.,* 2023). Furthermore, the logical development of next-generation gene editors with increased fidelity and targeting scopes can be facilitated by combining thorough molecular biochemistry with state-of-the-art biotechnological tools, such as high-resolution structural analyses, single-molecule studies, and sophisticated computational modeling (Wang *et al.,* 2024). In addition to overcoming current technological obstacles, this multidisciplinary collaboration seeks to open up new therapeutic possibilities, such as the treatment of intricate genetic illnesses, accurate epigenetic modification, and programmable RNA editing. This strategy lays the groundwork for novel, clinically feasible gene therapies with greater applicability, improved specificity, and reduced side effects by deepening our understanding of the biochemistry of gene editing components and their cellular milieu. In the end, this will revolutionize the fields of biotechnology and personalized medicine.

Uncharted Molecular Mechanisms in CRISPR Evolution

On top of that, the logical development of next-generation gene editors with increased fidelity and targeting scopes can be facilitated by combining thorough molecular biochemistry with state-of-the-art biotechnological tools, such as high-resolution structural analyses, single-molecule studies, and sophisticated computational modeling (Wang *et al.,* 2024). In addition to overcoming current technological obstacles, this multidisciplinary collaboration seeks to open up new therapeutic possibilities, such as the treatment of intricate genetic illnesses, accurate epigenetic modification, and programmable RNA editing. This strategy lays the groundwork for novel, clinically feasible gene therapies with greater applicability, improved specificity, and reduced side effects by deepening our understanding of the biochemistry of gene editing components and their cellular milieu. In the end, this will revolutionize the fields of biotechnology and personalized medicine (Nawaz *et al.,* 2024).

Biochemical Mapping of Underexplored Cas Proteins (Cas14, CasΦ, CasMINI)

Compact and phylogenetically different CRISPR-associated nucleases, Cas14, CasΦ (Cas-phi), and CasMINI have special characteristics that contradict conventional wisdom on the evolution and function of CRISPR. Cas14 is a very tiny single-effector nuclease (~400–700 amino acids) that targets single-stranded DNA (ssDNA) and does not require a PAM sequence (Savage *et al.,* 2019). It was found in DPANN archaea. Although its catalytic domain is structurally similar to that of RuvC, it differs from the bigger Cas9 or Cas12 proteins in terms of domain design. Recent research indicates that Cas14 activity is nevertheless impacted by flanking sequence context even if it lacks PAM-dependence, which may indicate cryptic PAM-like preferences or other specificity determinants.

Another ultra-compact CRISPR enzyme (~70 kDa) that remarkably preserves double-stranded DNA (dsDNA) cleavage capacity and programmable targeting is CasΦ, which is encoded by bacteriophages. It shows good editing fidelity with little off-target effects and has an integrated RuvC endonuclease domain. Crucially, its phage origin suggests that CRISPR diversification is driven by horizontal gene transfer (Watson *et al.,* 2018). A synthetically created variation of Cas12f, CasMINI, was tailored for editing the genomes of mammals. Although its activity is inherently modest in eukaryotic contexts, it combines purposefully chosen mutations with reduced RNA scaffolding to produce powerful gene control and editing in vivo. These small systems provide new opportunities for multiplexed and cell-type-specific genome editing and are particularly appealing for viral delivery, particularly in AAV vectors (Buchholz *et al.,* 2015).

Allosteric Modulation and Conformational Control of CRISPR Enzymes

The Cas9 and Cas12 families of CRISPR effectors function by precisely calibrated allosteric processes that synchronize nuclease activation, target DNA recognition, and guide RNA binding. Structural analyses of SpCas9 have shown that significant conformational changes are induced by sgRNA binding, pre-organizing the protein into a catalytically capable state (Skeparnias *et al.,* 2021). Long-range allosteric communication channels differently activate the HNH and RuvC nuclease domains. Local rearrangements in the REC and CTD domains are specifically triggered by PAM binding, and these changes have an impact on the catalytic core. Cas12a (Cpf1) has a novel mechanism in which a "lid" domain that regulates RuvC accessibility decouples DNA binding from cleavage. DNA unwinding and cleavage accuracy are improved by conformational changes surrounding the guide-target duplex. Allosteric engineering has made chemically inducible or optogenetic CRISPR systems possible. Examples of this include split-Cas designs and the logical insertion of ligand-binding domains. These methods increase therapeutic safety and specificity by using inherent conformational flexibility to produce conditionally active nucleases. Additionally, transitory intermediate phases in CRISPR activation have been shown by molecular dynamics simulations and cryo-EM studies, indicating new checkpoints for creating programmable specificity (Bhattacharya *et al.,* 2022).

Deciphering Non-Canonical PAM Recognition and Targeting Specificities

The targeting range of CRISPR enzymes has traditionally been determined by PAM recognition; however, some non-canonical and relaxed-PAM systems are currently being discovered, increasing the editing possibilities beyond the traditional NGG (for SpCas9) or TTTV (for AsCas12a) motifs. Through changes in the PAM-interacting domain, engineered Cas9 variants like xCas9 and SpCas9-NG show the ability to identify wider PAMs (Zhang *et al.,* 2020). By rewiring base-specific connections, these variations' modified hydrogen bonding networks enable the detection of hitherto unreachable genomic locations. PAM-equivalent motifs, such as protospacer flanking sites, or PFSs, exhibit a variety of metabolic needs in Cas12 and Cas13 systems. For example, although Cas13 enzymes target RNA without PAM requirements and instead rely on protospacer accessibility and sequence context, Cas12f orthologs frequently accept varied flanking sequences. As previously stated, Cas14 completely defies the PAM paradigm by demonstrating functional activity without the use of conventional PAMs, suggesting the possibility of an ancient editing system or a modification to mobile genomic components with little target limitations. SELEX-seq, PAM-SCANR, and multiplexed PAM libraries are examples of recent developments in high-throughput PAM discovery platforms that have sped up the profiling of non-canonical specificities across various CRISPR orthologs. In addition to improving target design, our results shed light on the evolutionary forces that influenced PAM diversity in various microbial ecologies (Van den Bergh *et al.,* 2018).

CRISPR + Enzyme Engineering Synergy

A novel avenue for biochemical manipulation and innovative therapeutics has been made possible by the combination of CRISPR technology with enzyme engineering. Beyond conventional genome editing, this synergistic integration is providing previously unheard-of control over gene regulation, molecular diagnostics, and targeted alterations.

Fusion of CRISPR with Epigenetic and RNA-Modifying Enzymes

RNA-modifying or epigenetic enzymes are coupled to dormant Cas proteins (dCas9 or dCas13). Without changing the genomic sequence, these fusion structures enable programmable regulation of gene expression. For example, site-specific epigenetic reprogramming is made possible by dCas9 coupled to DNA methyltransferases (DNMT3A) or demethylases (TET1), which facilitates research on gene regulation and the possible therapeutic reactivation of tumor suppressor genes that have been silenced (Neja *et al.,* 2020). A-to-I RNA editing at specific loci is made possible by fusing the RNA-targeting Cas13 with ADAR enzymes (adenosine deaminases acting on RNA). This provides a temporary and reversible method of repairing harmful point mutations at the transcript level.

Development of “Switchable” Cas Variants Controlled by Biochemical Stimuli

To precisely regulate CRISPR activity in both time and space, "switchable" or condition-dependent Cas variants have been developed. These systems are made to react to biological stimuli like light, redox conditions, or tiny molecules by becoming active or inactive. One tactic is to modify Cas9's conformation and function by designing it with ligand-binding domains (such as the estrogen receptor or abscisic acid receptors) to create allosteric switches (Mayer *et al.,* 2006). Another strategy uses split-Cas systems, in which a certain stimulus causes two inactive Cas9 fragments to reassemble into an active complex. By reducing off-target effects and enabling real-time management of gene editing activities, these responsive systems provide improved biosafety for in vivo applications.

Enhanced Biochemical Detection via Enzyme-Coupled CRISPR Diagnostics

Enzyme-coupling techniques have significantly enhanced CRISPR-based diagnostics, especially those that use the collateral cleavage activity of Cas12 and Cas13. To improve target nucleic acid detection, CRISPR enzymes are combined with pre-amplification enzymes (such as recombinase polymerase amplification or loop-mediated isothermal amplification) in systems like SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) and DETECTR. Additionally, colorimetric or electrochemical readouts are made possible by linking with reporter enzymes like alkaline phosphatase or HRP (horseradish peroxidase), which makes these systems suitable for point-of-care diagnostics (Shu *et al.,* 2021). When it comes to identifying genetic, bacterial, or viral biomarkers in clinical and environmental samples, this synergy greatly increases sensitivity, specificity, and practical utility.

AI-Guided Biochemical Design of Gene Editors

A revolutionary development in precision genome engineering is the incorporation of artificial intelligence (AI) into the biochemical architecture of gene editors (Dixit *et al.,* 2024). The optimization of guide RNAs (gRNAs) and protein-DNA interactions with AI assistance is one of the main innovations. Many biological datasets, including gRNA sequences, DNA target motifs, binding affinities, and cleavage efficiencies, are used to train machine learning algorithms, especially deep learning architectures like convolutional neural networks (CNNs) and recurrent neural networks (RNNs). These models anticipate sequence-dependent structural conformations and energy compatibility within the CRISPR-Cas complex, allowing for the logical design of gRNAs with high on-target activity and few off-target interactions. Furthermore, through structure-function optimization, AI models help develop protein interfaces (such as Cas9, Cas12, or base editors) to improve their specificity and catalytic efficiency. AI-driven evolution is based on an iterative feedback loop between in silico predictions and wet-lab biochemical experiments. High-throughput biochemical screening of gene editor variations informs AI model training, which in turn forecasts novel advantageous mutations or sequence configurations in this adaptive loop. The gene editing toolkit is gradually improved by empirically verifying these predictions and reintegrating the data into the learning system. The development of new Cas variants with modified PAM recognition profiles or decreased immunogenicity has been greatly aided by such closed-loop tuning (Teixeira *et al.,* 2024).

Furthermore, evaluating off-target effects requires the use of computer modeling. Together with AI classifiers, methods like ensemble docking, molecular dynamics simulations, and free energy perturbation (FEP) computations are employed to assess the likelihood and ramifications of off-target cleavage at the atomic level. AI algorithms that have been trained on biochemical and structural datasets can predict the genome's off-target binding landscapes, rank genomic locations according to the chance of cleavage, and recommend chemically altered gRNAs or Cas variations that reduce these risks. In addition, AI-enhanced molecular docking forecasts the binding kinetics and structural compatibility of modified Cas proteins with target and non-target DNA, enabling logical design choices that respect biophysical limitations (Barber *et al.,* 2025). These combined methods, combining computational modeling, AI prediction, and biochemical experimentation, offer a potent framework for creating next-generation gene editors that are not only functionally reliable but also biochemically accurate and therapeutically safer.

Quantum Biochemistry in CRISPR Systems

Exploring Quantum Tunneling and Chemical Reaction Mechanisms in CRISPR Activity

CRISPR-Cas systems, especially Cas9 and Cas12 nucleases, mediate precise genome editing through a series of coordinated biochemical steps involving DNA target recognition, cleavage, and repair. At the molecular level, these processes depend on highly specific chemical reactions, including nucleophilic attacks, proton transfers, and bond cleavage events (Walton *et al.,* 2021).

Quantum tunneling, a phenomenon where particles such as protons or electrons pass through energy barriers that classical physics predicts as insurmountable, has been increasingly recognized as a critical factor influencing enzymatic catalysis. In CRISPR nucleases, proton tunneling may facilitate the cleavage of phosphodiester bonds in the target DNA, enhancing reaction rates beyond classical expectations. This can affect the fidelity and efficiency of the DNA cleavage step by modulating transition state stabilization and lowering activation energy barriers (Joyce *et al.,* 2004).

Understanding these quanta tunneling effects provides insights into the fundamental limits of enzymatic precision and helps explain observed variations in reaction kinetics that are not fully accounted for by classical models.

Quantum Chemical Modeling of Editing Intermediates

Quantum chemical methods, such as Density Functional Theory (DFT), ab initio calculations, and hybrid quantum mechanics/molecular mechanics (QM/MM) simulations, are essential tools to model the electronic structure and energetics of CRISPR editing intermediates at atomic resolution.

These models enable detailed characterization of:

- The transition states during DNA strand cleavage and repair.
- The coordination of metal ions (e.g., Mg^{2+}) is crucial for catalytic activity.
- Conformational changes in the nuclease active site induced by guide RNA and DNA binding.
- Charge redistribution and bond rearrangements during catalysis.

By simulating the potential energy surfaces of these reactions, quantum chemical models can predict reaction pathways, identify rate-limiting steps, and suggest mutations or chemical modifications to enhance specificity or reduce off-target effects. Furthermore, these computational insights can guide the engineering of novel CRISPR variants with optimized kinetics and tailored functionalities (Bhattacharya *et al.,* 2022).

Prospects of Quantum Sensors for Dynamic Editing Monitoring

Emerging quantum sensor technologies offer unprecedented sensitivity and spatiotemporal resolution for monitoring biomolecular processes in real time. Quantum sensors leverage quantum coherence and entanglement phenomena—such as nitrogen-vacancy (NV) centers in diamond—to detect minute magnetic, electric, or chemical changes associated with enzymatic activity.

In the context of CRISPR:

- Quantum sensors can potentially monitor the dynamic conformational states of CRISPR-Cas complexes during DNA interrogation and cleavage.
- They can detect transient intermediate species and measure local electromagnetic fields produced by charge transfer events within the nuclease.
- Integration of quantum sensing platforms with single-molecule fluorescence or electrical readouts can enable label-free, in situ tracking of CRISPR editing events with nanometer precision.

These capabilities could revolutionize our understanding of CRISPR mechanisms, allow real-time quality control in genome editing applications, and open pathways for designing feedback-controlled editing systems with improved safety and efficacy (DeJulius *et al.,* 2024).

Table 1: Quantum Biochemistry in CRISPR Systems: Mechanisms, Modeling, and Monitoring via Quantum Sensors

Focus Area	Mechanistic / Target Detail	Evidence & Key Insights	Experimental / Theoretical Approaches	Challenges	Future Directions & Applications	Representative References
Hydrogen / Proton Transfer in Cas9 Catalysis	H-transfer during bond rearrangements in HNH domain may involve tunneling, impacting cleavage kinetics.	Enzyme catalysis literature shows tunneling significantly enhances rates; possible role in CRISPR cleavage chemistry.	Kinetic isotope effect studies, mixed quantum/classical dynamics, transition state theory with tunneling corrections.	Isolating tunneling signals in complex Cas9–DNA systems; biological decoherence.	Engineer Cas9 variants modulating tunneling via active-site electrostatics/dynamics.	Scrutton *et al.,* 2006; Sutcliffe 2000.
Proton Tunneling in DNA Base Pairs (Tautomerization)	Protons in H-bonds can tunnel between bases, forming tautomers that may affect target recognition/ fidelity.	Theoretical models predict tunneling-dominated tautomerization affecting mismatches/off-targets.	DFT-based double-well potential modeling; open quantum systems formalism.	Linking proton tunneling to off-target outcomes in vivo.	Incorporate tautomer probabilities into guide RNA design algorithms.	Slocombe *et al.,* 2021.
Concerted / Coherent Bond Cleavage	Hypothetical coordinated dual-strand break via quantum coherence or entanglement.	Theoretical proposals in restriction enzymes suggest coordinated bond-breaking; possible extrapolation to Cas9.	Quantum information modeling of DNA–protein complexes; decoherence analysis.	Lack of direct experimental proof; thermal noise limits coherence.	Synthetic systems to test decoherence shielding effects.	Kurian *et al.,* 2014.
Cas9 Catalytic Pathway with Quantum Implications	HNH domain's conformational transitions define geometry for potential tunneling or quantum contributions.	QM/MM free energy surfaces reveal subtle barriers conducive to tunneling modulation.	Ab initio QM/MM, cryo-EM structural refinement.	Scaling quantum models to entire Cas9–DNA complexes.	Hybrid instanton-based tunneling rate predictions for catalytic steps.	Van *et al.,* 2024; Palermo *et al.,*
Active-Site Transition State Modeling	Bond-breaking/forming events in HNH/RuvC domains with metal-ion assistance.	Energy barriers mapped; Mg^{2+} role clarified.	ai-QM/MM, enhanced sampling (metadynamics, umbrella sampling).	Computational cost, force-field partitioning.	Link models to kinetic mutagenesis assays for validation.	Nierzwicki *et al.,* 2022.
gRNA–DNA Hybrid Dynamics	Structural distortion by mismatches affects cleavage specificity.	Off-target tolerance linked to local alignment disruptions.	MD simulations with polarization corrections; QM/MM snapshots.	Capturing long-range effects, quantum redistribution.	Integrate with off-target mapping datasets.	Saha *et al.,* 2022.
Protonation & Metal Coordination	Protonation equilibria and Mg^{2+} coordination stabilize transition states.	QM/MM clarifies coupling of proton transfer and catalysis.	pKa shift calculations, DFT on active-site clusters.	pKa accuracy in heterogeneous environments.	Tailor ion-binding sites for specificity control.	Nierzwicki *et al.,* 2022.
NV-Center Diamond	Magnetic field shifts linked to	Nanoscale resolution,	Functionalization with	Coupling biochemical	Real-time monitoring of	Li *et al.,* RSC hybrid

Magnetometry	Cas9 binding/unbinding or cleavage events.	single-molecule sensitivity under ambient conditions.	molecular transducers; optical readout.	state changes to magnetic signals.	editing events in live cells.	sensing review.
Quantum Dynamic Response Protocols	Detect fast biochemical transients from CRISPR events.	Non-equilibrium response amplifies weak editing signals.	NV centers perturbed by controlled pulses; spectral analysis.	Calibration in biological noise.	Kinetic profiling of CRISPR in situ.	Ding *et al.,* 2024.
Quantum-Enhanced Biochemical Transduction	Convert gRNA–DNA binding into quantum-detectable changes.	Surpass classical limits via coherence-assisted readouts.	Hybrid constructs with magnetic nanoparticles & NV centers.	Coherence preservation in bio interfaces.	Off-target early warning systems.	RSC hybrid quantum sensing chapter 2024.
Biosensor–Quantum Fusion	CRISPR reporter cleavage linked to quantum readout shifts.	Combines CRISPR specificity with quantum sensitivity.	Reporter molecules altering local fields upon cleavage.	Designing efficient coupling in complex media.	Multiplexed editing validation with orthogonal readouts.	ORNL biosensor studies.

Bioorthogonal CRISPR for Precision Therapy

Bioorthogonal CRISPR for Precision Therapy represents a transformative leap in genome editing, enabling unparalleled specificity and safety through the integration of 1073 iorthogonal chemistry and disease-responsive mechanisms (Liu *et al.,* 2025). One of the most promising strategies in this realm involves disease-specific biochemical activation of CRISPR editors, where the activity of genome editing tools is selectively turned on only in the presence of pathological markers, such as cancer-specific enzymes, tumor acidosis, or inflammatory proteases. This approach minimizes off-target effects in healthy tissues and enhances the precision of therapeutic interventions. To further refine spatiotemporal control, 1073 iorthogonal ligands, engineered molecules that do not interfere with native biological pathways, are employed to "switch on" or "lock" CRISPR systems in a highly controllable manner. These ligands can be activated by external stimuli (e.g., light, temperature, or ultrasound) or internal disease signals, ensuring that editing occurs only at the desired time and location (Zhuo *et al.,* 2021). Moreover, recent innovations in redox-sensitive Cas enzymes take advantage of the oxidative stress typically found in diseased microenvironments, such as tumors or sites of chronic inflammation. These Cas variants remain inactive under normal redox conditions but become catalytically active in response to elevated reactive oxygen species (ROS), enabling localized genome editing where it is most needed. Together, these strategies form a new frontier in therapeutic genome engineering, where CRISPR tools are reprogrammed not only to target specific genetic sequences but also to respond intelligently to the biochemical context of disease, ensuring greater efficacy, reduced side effects, and enhanced patient safety (Kumar *et al.,* 2025).

CRISPR in Microbiome Reprogramming via Metabolic Pathway Editing

CRISPR technology is emerging as a powerful tool for microbiome reprogramming, particularly through the precise editing of metabolic pathways in microbial communities that reside in the human body (Ramachandran *et al.,* 2019). One groundbreaking application lies in modifying microbial genes that influence host neurotransmitter production, such as those involved in the synthesis of serotonin, dopamine, and gamma-aminobutyric acid (GABA). These neurotransmitters, although primarily associated with the central nervous system, are significantly regulated by gut microbiota, forming the basis of the gut-brain axis. By leveraging CRISPR-Cas systems, scientists can now edit key microbial genes to upregulate or suppress specific enzymatic activities, thereby controlling the metabolic outputs that directly impact host neurochemistry and emotional health. Moreover, CRISPR-based rewiring of microbial metabolism extends beyond neurotransmitters to include the production of beneficial short-chain fatty acids, bile acids, and other bioactive molecules that influence immune modulation, inflammation, and energy balance (Nazir *et al.,* 2024). This precision metabolic engineering not only offers novel therapeutic strategies for mood disorders, neurodegenerative diseases, and metabolic syndromes but also reveals a deeper biochemical interplay between microbial CRISPR elements and host physiological systems. The engineered microbes can be designed to respond to environmental or dietary cues, creating a dynamic and responsive symbiosis between host and microbiota. Such advancements highlight CRISPR's transformative potential in developing next-generation biotherapeutics aimed at holistic health optimization through the gut microbiome (Patra *et al.,* 2024).



Fig 1: CRISPR in Microbiome Reprogramming via Metabolic Pathway Editing

Synthetic Organelle-Based CRISPR Delivery

Synthetic Organelle-Based CRISPR Delivery represents a groundbreaking innovation in the field of gene editing, offering a highly localized and efficient method of intracellular CRISPR system deployment (Farooq *et al.,* 2025). By designing membrane-less organelles, biomolecular condensates formed via liquid–liquid phase separation (LLPS)—researchers can create controlled, phase-separated microenvironments that concentrate CRISPR-Cas components exactly where they are needed inside the cell. These synthetic organelles mimic the behavior of natural cellular condensates like nucleoli or stress granules but are engineered to act as CRISPR activity centers, thereby enabling highly specific and spatially confined editing actions. This approach eliminates the need for Cas proteins to rely solely on nuclear transport, a major bottleneck in traditional delivery strategies, especially in non-dividing or hard-to-transfect cells. These nanobioreactors, often formed by fusing intrinsically disordered proteins or RNA scaffolds with CRISPR effectors, serve not only as protective hubs that shield CRISPR complexes from premature degradation but also as platforms for co-localizing DNA templates and repair machinery to optimize editing outcomes (Mauvais *et al.,* 2025). Furthermore, these artificial compartments can be programmed to respond to cellular cues—such as pH, redox status, or light—allowing dynamic control over CRISPR activation in both time and space. This strategy holds transformative potential for therapeutic genome editing, as it provides a non-viral, tunable, and less immunogenic alternative for CRISPR delivery, particularly suitable for precision medicine applications in oncology, neurology, and regenerative biology (Banerjee *et al.,* 2024).

Circular RNAs and Biochemical Editing Loops

Circular RNAs and Biochemical Editing Loops represent a cutting-edge intersection in synthetic biology, offering promising routes for achieving sustained, precise, and context-responsive genome editing (Abdi *et al.,* 2024). Circular RNAs (circRNAs), owing to their covalently closed loop structures, exhibit remarkable stability compared to linear RNAs, making them ideal candidates for long-lasting expression in therapeutic and research settings. When engineered as guides for CRISPR systems, these circRNAs can enable durable editing effects, avoiding rapid degradation and providing a consistent editing signal over time. This property is particularly advantageous in tissues with low cell turnover or in chronic disease models where repeated delivery of editing components is impractical or inefficient. Furthermore, by designing cell-type-specific circular RNA switches, researchers can restrict CRISPR activity to particular cellular contexts, ensuring precision and minimizing off-target effects. These switches often rely on microRNA binding sites or specific RNA-binding protein motifs embedded within the circRNA to act as logic gates that activate or suppress editing based on the cell's molecular profile (Kameda *et al.,* 2023). Additionally, leveraging endogenous RNA biochemistry, such as natural splicing machinery, self-splicing introns, or ribozyme-based self-circularization strategies, enhances the regulatory control and functional efficiency of these synthetic circRNA systems. This integration of circular RNA platforms with CRISPR-based editing not only opens new avenues for programmable and self-limiting gene therapies, but also fosters the emergence of biochemical feedback loops, wherein RNA molecules dynamically respond to cellular states and adjust gene editing output accordingly—paving the way for a new era of autonomous, self-regulating genetic interventions (Grinin *et al.,* 2024).

Table 2: Circular RNAs and Biochemical Editing Loops: Mechanisms, Components, Advantages, Limitations, and Applications

Mechanism / Strategy	Key Molecular Components	Advantages	Limitations / Challenges	Applications / Future Directions
Stable circular RNA–guided CRISPR for durable editing effects	Circularized gRNAs via ribozyme self-splicing or enzymatic ligation, CRISPR effector proteins (Cas9, Cas12a), RNA-stabilizing motifs	Prolonged editing activity; resistance to exonuclease degradation; reduced dosing frequency	Complex design and synthesis; risk of off-target effects due to extended activity; immune response potential	Chronic disease gene correction; in vivo editing where re-dosing is impractical; integration with base or prime editing for precise, long-lived corrections
Cell-type-specific editing via circular RNA switches	Endogenous RNA markers; engineered RNA sensors (e.g., CellREADR); programmable toehold switches; RNA-triggered gRNAs	High cell-type specificity; rapid activation; avoids reliance on surface markers	Difficulty in distinguishing closely related transcriptomes; potential background activation; complex multi-component delivery	Neuron subtype-specific modulation; cancer-cell-restricted therapy; immune cell subtype targeting; lineage tracing
Leveraging miRNA sponge activity for editing control	Circular RNAs with multiple miRNA binding sites; target mRNAs; endogenous miRNAs	Indirect pathway modulation; cell-state-dependent CRISPR activation; tunable editing strength	High expression needed for competitive binding; may alter native miRNA networks; cell context dependency	Off-target suppression in undesired cell types; synthetic circRNA “filters” in editing circuits; dynamic tuning of activity based on miRNA profiles
RBP scaffolding or decoy interactions	Circular RNAs with RNA-binding protein recognition motifs (e.g., HuR, NF90/NF110); engineered fusion proteins	Spatial/temporal control of editing; context-aware complex assembly; modulation without DNA changes	Prediction difficulty for RNA–protein interactions; potential competition with native functions; toxicity risk	Conditional assembly of CRISPR machinery; targeted recruitment of cofactors; disease-specific activation circuits
Harnessing endogenous ADAR-mediated editing for control	ADAR enzymes; engineered RNA duplex motifs; RNA-sensing translation activation platforms	Minimal synthetic footprint; exploits native enzymes; high signal fidelity from endogenous RNA detection	Variable ADAR expression across tissues; editing efficiency inconsistencies; promiscuity risk	Cell-type-specific CRISPR activation; RNA-editing feedback loops; biomarker-driven therapy gating
Synthetic gene circuit layering with RNA inputs	Toehold switches; modular circular RNA sensors; transcriptional and post-transcriptional controllers	Multi-input specificity; robust conditional activation; noise reduction in editing	Circuit complexity; host burden; tuning dynamic range	AND/NOT logic-gated editing; combinatorial biomarker-based activation; adaptive therapeutic circuits
Therapeutic delivery using circRNA scaffolds	Synthetic circular RNA constructs; lipid nanoparticles (LNPs); viral vectors	Long-lived expression; lower immune detection; reduced dosing needs	Manufacturing complexity; targeted delivery limitations; modification-dependent immunogenicity	Hybrid circRNA–CRISPR delivery vehicles; stable multi-module editing payloads; self-limiting therapeutic windows
Endogenous feedback loop integration	CircRNAs responsive to stress-induced or disease-specific RNAs; coupled activator/inhibitor modules	Autonomous self-regulation; adaptive editing strength; reduced manual intervention	Requires deep understanding of disease transcriptomics; potential feedback instability	Auto-regulated editing in fluctuating disease states; closed-loop gene therapy systems
Multiplexed editing with modular circular RNA platforms	Multiple gRNA sequences embedded in a single circRNA scaffold	Coordinated multi-locus editing; simplified delivery of multiple guides	Structural stability challenges; increased off-target possibilities	Treating polygenic disorders; synthetic biology applications needing parallel edits
Circular RNA-based prime/base editing control	Circular scaffolds encoding pegRNA or base-editing gRNAs	Increased stability of editing templates; extended correction windows	Complex pegRNA circularization; precise folding needed for activity	Durable base/prime editing in stem cells; long-term functional restoration in tissues

Trans-Biological System Editing (Cross-Kingdom CRISPR)

The concept of Trans-Biological System Editing, often referred to as Cross-Kingdom CRISPR, represents a groundbreaking frontier in gene editing where tools such as CRISPR-Cas systems are applied beyond traditional single-species boundaries to manipulate the genomes of organisms across different biological kingdoms—such as plants, microbes, and viruses—in a coordinated and synergistic manner (Berg *et al.,* 2020). This ambitious approach aims not only to engineer traits in individual organisms but also to construct novel biochemical communication pathways that enable synthetic symbiosis, allowing for intelligent interactions between host plants and their associated microbiota or viral vectors. For instance, gene-edited endophytic bacteria could be designed to modulate plant stress responses or nutrient uptake in real-time, while modified plant genomes could be tailored to emit specific molecular signals that coordinate with engineered microbial communities. However, cross-kingdom editing introduces complex challenges, especially in overcoming biochemical barriers such as differences in codon usage, immune rejection, and host-specific regulatory pathways that hinder the stable expression and functionality of foreign genetic material (Razin *et al.,* 1998). Advanced delivery systems, such as nanocarriers and viral-like particles, combined with synthetic promoters and regulatory circuits, are being developed to bridge these inter-kingdom gaps. Furthermore, the integration of AI-driven design tools and multi-omic analyses helps in predicting compatibility and refining genetic circuits to function seamlessly across biological domains. Ultimately, Trans-Biological System Editing could revolutionize agriculture, bioremediation, and therapeutic development by enabling programmable ecosystems in which organisms across kingdoms co-evolve with tailored genetic functions, reshaping the future of synthetic biology (Strathdee *et al.,* 2023).

CRISPR as a Neuromolecular Modulator

The application of CRISPR as a neuromolecular modulator marks a transformative advancement in neurobiotechnology, offering precise genomic interventions to modulate synaptic genes implicated in memory formation and mood regulation (Singh *et al.,* 2023). Emerging research highlights the use of CRISPR-Cas systems to edit genes such as *BDNF*, *CREB*, and *SLC6A4*, which play pivotal roles in synaptic plasticity, neurotransmitter transport, and emotional processing. These targeted interventions aim to reverse the molecular underpinnings of neuropsychiatric disorders like depression, anxiety, PTSD, and cognitive decline by restoring normal gene function or enhancing neuroprotective gene expression. Beyond synapses, CRISPR-based tools are increasingly being adapted for biochemical modulation of ion channels, such as those encoding voltage-gated potassium and calcium channels, which govern neuronal excitability and signal propagation. Moreover, mitochondrial dysfunction—central to several neurodegenerative diseases—is being addressed through mitochondrial-targeted CRISPR variants that regulate genes involved in ATP production, oxidative stress management, and apoptotic signaling. These strategies represent a convergence of neurogenomics and molecular biochemistry, enabling cell-type-specific, temporally controlled interventions (Lein *et al.,* 2017). Therapeutically, neurobiochemical CRISPR tools such as CRISPRa/i (activation/interference) and base editors are being explored to fine-tune neural circuits without inducing double-stranded breaks, offering a safer alternative for chronic neurological conditions. The future holds promise for integrating CRISPR with brain-targeted delivery systems (e.g., AAVs, nanoparticles) and real-time neural monitoring to achieve personalized neuromodulation, paving the way for next-generation therapeutics in neuropsychiatry and cognitive medicine (Wang *et al.,* 2024).

CONCLUSION

Recent advancements in the biochemical mechanisms underlying CRISPR systems have significantly expanded the toolkit's precision and versatility, revealing intricate structural and catalytic insights that allow for more refined target recognition, minimized off-target effects, and enhanced control over gene editing outcomes. Engineered variants such as base editors, prime editors, and CRISPR-associated transposases exemplify how deep biochemical understanding continues to transform CRISPR into a precise, programmable molecular tool. Beyond these mechanistic breakthroughs, the convergence of biochemistry with artificial intelligence and nanotechnology is redefining the possibilities of gene editing. AI-driven guide RNA design, predictive modeling of off-target profiles, and nanocarrier-mediated delivery systems are fostering a new era of smart and efficient genome engineering. These interdisciplinary integrations promise not only increased specificity and safety but also adaptability across diverse cell types and therapeutic contexts. Looking forward, the future of gene editing lies in creating safer, smarter, and highly customizable gene therapies tailored to individual genomic profiles—ushering in the age of precision medicine. However, as these technologies become more powerful, they raise profound ethical and regulatory challenges. Societal oversight, equitable access, biosecurity concerns, and the implications of germline editing must be addressed through comprehensive governance frameworks. The path forward must balance innovation with responsibility to ensure that next-generation gene editing evolves in a direction that is ethically sound, socially inclusive, and scientifically robust.

REFERENCE

- Abdi, G., Patil, N., Tendulkar, R., Dhariwal, R., Mishra, P., Tariq, M., ... & Mudgal, G. (2024). Engineering Genomic Landscapes: Synthetic

Biology Approaches in Genomic Rearrangement. In *Advances in Genomics: Methods and Applications* (pp. 227-264). Singapore: Springer Nature Singapore.

- Allen, A., Cooper, B. H., Singh, J., Rohs, R., & Qin, P. Z. (2025). PAM-adjacent DNA flexibility tunes CRISPR-Cas12a off-target binding. *Scientific Reports*, *15*(1), 4930.
- Banerjee, D., Bhattacharya, A., Puri, A., Munde, S., Mukerjee, N., Mohite, P., ... & Al Shmrany, H. (2024). Innovative approaches in stem cell therapy: revolutionizing cancer treatment and advancing neurobiology–a comprehensive review. *International Journal of Surgery*, *110*(12), 7528-7545.
- Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O'Reilly, D. (2025). Chemical engineering of CRISPR–Cas systems for therapeutic application. *Nature Reviews Drug Discovery*, *24*(3), 209-230.
- Berg, G., Rybakova, D., Fischer, D., Cernava, T., Vergès, M. C. C., Charles, T., ... & Schloter, M. (2020). Microbiome definition re-visited: old concepts and new challenges. *Microbiome*, *8*(1), 103.
- Bhattacharya, S., & Satpati, P. (2022). Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. *ACS omega*, *8*(2), 1817-1837.
- Bhattacharya, S., & Satpati, P. (2022). Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. *ACS omega*, *8*(2), 1817-1837.
- Buchholz, C. J., Friedel, T., & Büning, H. (2015). Surface-engineered viral vectors for selective and cell-type-specific gene delivery. *Trends in biotechnology*, *33*(12), 777-790.
- Burgess, S. M. (2020). Genome editing by targeted nucleases and the CRISPR/Cas revolution. *The Liver: Biology and Pathobiology*, 953-964.
- Butt, H., Eid, A., Ali, Z., Atia, M. A., Mokhtar, M. M., Hassan, N., ... & Mahfouz, M. M. (2017). Efficient CRISPR/Cas9-mediated genome editing using a chimeric single-guide RNA molecule. *Frontiers in Plant Science*, *8*, 1441.
- Cebrian-Serrano, A., & Davies, B. (2017). CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools. *Mammalian Genome*, *28*(7), 247-261.
- Chanchal, D. K., Chaudhary, J. S., Kumar, P., Agnihotri, N., & Porwal, P. (2024). CRISPR-based therapies: Revolutionizing drug development and precision medicine. *Current Gene Therapy*, *24*(3), 193-207.
- DeJulius, C. R., Walton, B. L., Colazo, J. M., d'Arcy, R., Francini, N., Brunger, J. M., & Duvall, C. L. (2024). Engineering approaches for RNA-based and cell-based osteoarthritis therapies. *Nature Reviews Rheumatology*, *20*(2), 81-100.
- Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. D. R., & Ramu Krishnan, N. (2024). Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. *Frontiers in bioengineering and biotechnology*, *11*, 1335901.
- Farooq, M. U., Lawrie, C. H., & Deng, N. N. (2025). Solving Mazes of Organelle-Targeted Therapies with DNA Nanomachines. *Advanced Materials*, 2508047.
- Grinin, L., Grinin, A., & Korotayev, A. (2024). Biotechnologies in Perspective: Major Breakthroughs, Development of Self-regulating Systems and Possible Social Confrontations. In *Cybernetic Revolution and Global Aging: Humankind on the Way to Cybernetic Society, or the Next Hundred Years* (pp. 371-401). Cham: Springer International Publishing.
- Gupta, R. M., & Musunuru, K. (2014). Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. *The Journal of Clinical Investigation*, *124*(10), 4154-4161.
- Hu, L. F., Li, Y. X., Wang, J. Z., Zhao, Y. T., & Wang, Y. (2023). Controlling CRISPR-Cas9 by guide RNA engineering. *Wiley Interdisciplinary Reviews: RNA*, *14*(1), e1731.
- Joyce, C. M., & Benkovic, S. J. (2004). DNA polymerase fidelity: kinetics, structure, and checkpoints. *Biochemistry*, *43*(45), 14317-14324.
- Kameda, S., Ohno, H., & Saito, H. (2023). Synthetic circular RNA switches and circuits that control protein expression in mammalian cells. *Nucleic Acids Research*, *51*(4), e24-e24.
- Kumar, A. V., Garg, V. K., & Buttar, H. S. (2025). Harnessing CRISPR/Cas systems for tailored therapeutic interventions in molecular medicine: Advancements in precision medicine and enhanced patient care. In *Molecular Medicine and Biomedical Research in the Era of Precision Medicine* (pp. 397-425). Academic Press.
- Lein, E., Borm, L. E., & Linnarsson, S. (2017). The promise of spatial transcriptomics for neuroscience in the era of molecular cell typing. *Science*, *358*(6359), 64-69.
- Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020). Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. *Signal transduction and targeted therapy*, *5*(1), 1.
- Liu, X., Zhou, E., Qi, Q., Xiong, W., Tian, T., & Zhou, X. (2025). Innovative Chemical Strategies for Advanced CRISPR Modulation. *Accounts of Chemical Research*, *58*(8), 1262-1274.
- Mauvais, F. X., Hamel, Y., Silvin, A., Mulder, K., Hildner, K., Akyol, R., ... & van Endert, P. (2025). Metallophilic marginal zone macrophages cross-

prime CD8+ T cell-mediated protective immunity against blood-borne tumors. *Immunity*, *58*(4), 843-860.

- Mayer, G., & Heckel, A. (2006). Biologically active molecules with a "light switch". *Angewandte Chemie International Edition*, *45*(30), 4900-4921.
- Nawaz, A. (2024). The Role of Biotechnology in Personalized Medicine: Tailoring Treatments through Genomic Insights. *Life Sciences Perspectives*, *1*(02), 129-139.
- Nazir, A., Hussain, F. H. N., & Raza, A. (2024). Advancing microbiota therapeutics: The role of synthetic biology in engineering microbial communities for precision medicine. *Frontiers in Bioengineering and Biotechnology*, *12*, 1511149.
- Neja, S. A. (2020). Site-specific DNA demethylation as a potential target for cancer epigenetic therapy. *Epigenetics insights*, *13*, 2516865720964808.
- Ochiai, H., & Yamamoto, T. (2014). Genome editing using zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). In *Targeted genome editing using site-specific nucleases: ZFNs, TALENs, and the CRISPR/Cas9 system* (pp. 3-24). Tokyo: Springer Japan.
- Patra, D. (2024). Synthetic biology-enabled engineering of probiotics for precision and targeted therapeutic delivery applications. *Exon*, *1*(2), 54-66.
- Rallapalli, K. L., & Komor, A. C. (2023). The design and application of DNA-editing enzymes as base editors. *Annual review of biochemistry*, *92*(1), 43-79.
- Ramachandran, G., & Bikard, D. (2019). Editing the microbiome the CRISPR way. *Philosophical Transactions of the Royal Society B*, *374*(1772), 20180103.
- Razin, S., Yogev, D., & Naot, Y. (1998). Molecular biology and pathogenicity of mycoplasmas. *Microbiology and molecular biology reviews*, *62*(4), 1094-1156.
- Saber Sichani, A., Ranjbar, M., Baneshi, M., Torabi Zadeh, F., & Fallahi, J. (2023). A review on advanced CRISPR-based genome-editing tools: base editing and prime editing. *Molecular Biotechnology*, *65*(6), 849-860.
- Sampath, V., Rangarajan, N., Sharanappa, C. H., Deori, M., Veeraragavan, M., Ghodake, B. D., & Kaushal, K. (2023). Advancing crop improvement through CRISPR technology in precision agriculture trends review. *International Journal of Environment and Climate Change*, *13*(11), 4683-4694.
- Savage, D. F. (2019). Cas14: big advances from small CRISPR proteins. *Biochemistry*, *58*(8), 1024-1025.
- Shu, T., Hunter, H., Zhou, Z., Sun, Y., Cheng, X., Ma, J., ... & Serpe, M. J. (2021). Portable point-of-care diagnostic devices: an updated review. *Analytical Methods*, *13*(45), 5418-5435.
- Singh, M., Agarwal, V., Jindal, D., Pancham, P., Agarwal, S., Mani, S., ... & Jha, S. K. (2023). Recent updates on corticosteroid-induced neuropsychiatric disorders and theranostic advancements through gene editing tools. *Diagnostics*, *13*(3), 337.
- Skeparnias, I., & Zhang, J. (2021). Cooperativity and interdependency between RNA structure and RNA–RNA interactions. *Non-coding RNA*, *7*(4), 81.
- Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023). Phage therapy: From biological mechanisms to future directions. *Cell*, *186*(1), 17-31.
- Teixeira, A. P., & Fussenegger, M. (2024). Synthetic gene circuits for regulation of next-generation cell-based therapeutics. *Advanced Science*, *11*(8), 2309088.
- Van den Bergh, B., Swings, T., Fauvart, M., & Michiels, J. (2018). Experimental design, population dynamics, and diversity in microbial experimental evolution. *Microbiology and Molecular Biology Reviews*, *82*(3), 10-1128.
- Walton, J. C. (2021). Dissociations of free radicals to generate protons, electrophiles or nucleophiles: role in DNA strand breaks. *Chemical Society Reviews*, *50*(13), 7496-7512.
- Wang, H., Shi, C., Jiang, L., Liu, X., Tang, R., & Tang, M. (2024). Neuroimaging techniques, gene therapy, and gut microbiota: Frontier advances and integrated applications in Alzheimer's Disease research. *Frontiers in aging neuroscience*, *16*, 1485657.
- Wang, M., Lin, H., Lin, H., Du, P., & Zhang, S. (2024). From species to varieties: How modern sequencing technologies are shaping Medicinal Plant Identification. *Genes*, *16*(1), 16.
- Wang, M., Lin, H., Lin, H., Du, P., & Zhang, S. (2024). From species to varieties: How modern sequencing technologies are shaping Medicinal Plant Identification. *Genes*, *16*(1), 16.
- Watson, B. N., Staals, R. H., & Fineran, P. C. (2018). CRISPR-Cas-mediated phage resistance enhances horizontal gene transfer by transduction. *MBio*, *9*(1), 10-1128.
- Zhang, C., Kang, G., Liu, X., Zhao, S., Yuan, S., Li, L., ... & Yang, J. (2020). Genome engineering in plant using an efficient CRISPR-xCas9 toolset with an expanded PAM compatibility. *Frontiers in Genome Editing*, *2*, 618385.
- Zhuo, C., Zhang, J., Lee, J. H., Jiao, J., Cheng, D., Liu, L., ... & Li, M. (2021). Spatiotemporal control of CRISPR/Cas9 gene editing. *Signal Transduction and Targeted Therapy*, *6*(1), 238.